Roswell Park’s Dr. Kunle Odunsi Gives Update on Ovarian Cancer Immunotherapy Study at ASCO Annual Meeting

Reports on status of ongoing clinical study involving T-cell engineering

Article ID: 675966

Released: 6-Jun-2017 12:05 PM EDT

Source Newsroom: Roswell Park Cancer Institute

  • Credit: Roswell Park Cancer Institute

    Dr. Kunle Odunsi of Roswell Park Cancer Institute

Newswise — BUFFALO, N.Y. — Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director of Roswell Park Cancer Institute, presented an update about an ongoing clinical trial at the American Society of Clinical Oncology (ASCO) 53rd Annual Meeting in Chicago. Dr. Odunsi, who is also Chair of Gynecologic Oncology and Executive Director of the Center for Immunotherapy at Roswell Park, reported on the status and methods of the clinical study, which is assessing the safety and antitumor activity of an approach that employs T-cell engineering to stimulate the immune system against ovarian cancer. 

The clinical study is being conducted in collaboration with researchers from City of Hope, the Stanford Cancer Institute, the University of Texas MD Anderson Cancer Center, the University of Miami and Adaptimmune Therapeutics.

The premise behind the ongoing phase I/II clinical trial in patients with recurrent or treatment-resistant ovarian cancer is to use T-cell engineering to “teach” a patient’s own immune system to recognize and attack the ovarian cancer cells. After patients receive a lymphodepleting chemotherapy regimen, their T cells are isolated, expanded, transduced with a lentiviral vector containing specialized T-cell receptors (TCRs) — specifically, the NY-ESO-1c259 TCRs — and then infused intravenously.

“There is a pressing need for new therapies for ovarian cancer and for epithelial ovarian cancer in particular,” says Dr. Odunsi, who holds an additional faculty appointment at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo. “We’re pleased to be able to detail our progress on this study for our colleagues around the country and around the world.”

The poster, “A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891),” is ASCO 2017 abstract TPS3094.

This release is also available in the Roswell Park online newsroom: https://www.roswellpark.org/media/news/roswell-parks-dr-kunle-odunsi-give-update-ovarian-cancer-immunotherapy-study-asco-annual

###

The mission of Roswell Park Cancer Institute (RPCI) is to understand, prevent and cure cancer. Founded in 1898, RPCI is one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and remains the only facility with this designation in Upstate New York. The Institute is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation’s leading cancer centers; maintains affiliate sites; and is a partner in national and international collaborative programs. For more information, visit www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or email askrpci@roswellpark.org. Follow Roswell Park on Facebook and Twitter.


Comment/Share





Chat now!